Argenx SE is attracting significant investor attention following recent developments regarding its autoimmune drug Vyvgart. Updates on the company's broader drug pipeline are also contributing to the heightened focus.
Argenx (ARGX) Draws Investor Focus on Vyvgart Updates, Pipeline News
|1 min read
BiotechnologyDrug DevelopmentARGXPharmaceuticalsInvestor Focus
